Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for tuberculosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration. Among HIV-positive patients who received treatment for active tuberculosis, thiacetazone has been associated with cutaneous hypersensitivity and recurrent tuberculosis. No controlled trials have investigated the safety and efficacy of thiacetazone-containing regimens compared with alternative regimens (...) among patients with HIV. In a randomised clinical trial of 191 HIV-positive patients with active pulmonary tuberculosis, we examined the safety and short-term efficacy of isoniazid, rifampicin, and pyrazinamide for two months followed by isoniazid and rifampicin for seven months (RHZ) compared with streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for ten months (STH). Between May, 1990, and September, 1991, 191 HIV-positive adult Ugandan patients
1994LancetControlled trial quality: predicted high
The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis: a cost-effectiveness analysis The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis: a cost-effectiveness analysis The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis: a cost-effectiveness analysis Adal K A, Anglim A M, Palumbo C L, Titus M G, Coyner B J, Farr B M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of high-efficiency particulate air filters (HEPA respirators) to protect hospital workers from tuberculosis. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis
Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature Colditz G A, Brewer T F, Berkey C S, Wilson M E, Burdick E, Fineberg H V, Mosteller F Authors' objectives To quantify the efficacy of BCG vaccine against tuberculosis (TB). Searching MEDLINE (...) was searched using the terms 'BCG vaccine', 'tuberculosis' and 'human'. Bibliographies of retrieved studies and review papers were examined for additonal material, and the World Health Organization (WHO) and the Centre for Disease Control and Prevention (CDC) were contacted for unpublished trials. Studies and trials in any language were considered. Study selection Study designs of evaluations included in the review Prospective trials and case-control studies measuring the efficacy of BCG vaccination
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Tuberculosis occurring with human immunodeficiency virus (HIV) infection is a serious and growing public health problem. We have carried out a randomised clinical trial of a 12-month course of isoniazid plus vitamin B6 versus vitamin B6 alone in Port-au-Prince, Haiti, to assess the efficacy of isoniazid in preventing active tuberculosis in symptom-free HIV-infected individuals. The effect (...) of prophylaxis on the development of HIV disease, AIDS, and death was also investigated. 118 subjects were assigned treatment with isoniazid plus B6 (n = 58) or B6 alone (n = 60) between 1986 and 1989. The treatment groups were similar at study entry in demographic, clinical, and immunological characteristics. Interim analysis in 1990 revealed no significant difference in tuberculosis outcome measures. Follow-up was continued until 1992, at which time significant protection by isoniazid against
The continuing challenge of tuberculosis The continuing challenge of tuberculosis The continuing challenge of tuberculosis Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Office of Technology Assessment. The continuing (...) challenge of tuberculosis. U. S. Congress. Office of Technology Assessment (OTA). OTA-H-574. 1993 Authors' objectives To synthesize current understanding of tuberculosis in the United States and to provide an overview of Federal government involvement in its control. Authors' conclusions The report analyzes the pros and cons of several options for Congressional consideration that have been suggested as potential ways to help control TB. Project page URL Indexing Status Subject indexing assigned by CRD
Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. A randomised controlled trial compared the effectiveness and toxicity in pulmonary tuberculosis of two drug regimens containing rifampicin and isoniazid given daily or twice-weekly for 4 months after a 2-month period of intensive treatment with daily isoniazid, rifampicin, and pyrazinamide. 667 patients with newly diagnosed pulmonary tuberculosis were randomly allocated to continue daily treatment with isoniazid (400 (...) with bacteriological failure (at least one positive sputum culture with more than 20 colonies) or who had died from tuberculosis (17 [6%] vs 10 [3%]). Nor was there a significant difference in the relapse rate (17 [7%] treated daily vs 10 [4%] treated twice-weekly) during follow-up of 12 months. Thus, the twice-weekly regimen was at least as effective as the daily regimen for treatment of pulmonary tuberculosis.
Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis Rose D N, Schechter C B, Fahs M C, Silver A L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Tuberculosis (TB) prevention. Type of intervention Primary prevention Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Men aged 20, recently infected with tubercle bacillus and thus at high risk and men aged 55, with no risk factors other than long term presence of tubercle bacillus (low risk). Setting The study was carried out in the USA
Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Five 6-month antituberculosis regimens, allocated at random to patients with acid-fast bacilli in their sputum on microscopy, were studied. Four, given three times a week from the start, contained isoniazid and rifampicin together with (1) streptomycin, pyrazinamide, and ethambutol, (2) streptomycin and pyrazinamide, (3) streptomycin and ethambutol, or (4) pyrazinamide
Sputum-smear-negative pulmonary tuberculosis: controlled trial of 3-month and 2-month regimens of chemotherapy. Of 1072 Chinese patients with radiographically active pulmonary tuberculosis and no microscopic evidence of acid-fast bacilli in sputum examinations, only 691 (64%) were sputum-culture negative. All patients were randomly allocated to selective chemotherapy (antituberculosis chemotherapy not being started until the activity of the disease had been confirmed), to daily streptomycin
Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils. Five 4-mo regimens of chemotherapy for tuberculosis are compared. The two regimens in which rifampicin was given throughout the 4 mo were associated with bacteriological-relapse rates of 8% in the first 6 mo after stopping chemotherapy, but the three regimens in which rifampicin was given for only the first 2 mo
Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. A rigimen of rifampicin plus isoniazid, supplemented in the first two months by ethambutol or streptomycin, was given for six, nine, twelve, or eighteen months in a controlled study of 696 patients with culture-positive pulmonary tuberculosis. The results obtained in the thirty-three months since the start of treatment when all the patients in the six-month and nine (...) plus isoniazid for nine months, supplemented by ethambutol in a dose of 25 mg/kg for the first two months, is now acceptable as standard chemotherapy for pulmonary tuberculosis in Britain.
Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. The results of short courses of chemotherapy using rifampicin plus isoniazid, supplemented for the first two months by streptomycin or ethambutol, in patients with newly diagnosed pulmonary tuberculosis, have been studied. 174 patients with little or no cavitation received six months chemotherapy. 1 (0.6%) failed to convert to culture negative during treatment and 5 (3
Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. A total of 481 adult Chinese, Malays, and Indians in Singapore with newly diagnosed smear-positive pulmonary tuberculosis were allocated at random to four regimens of intermittent rifampicin plus isoniazid. All patients received an initial 2 weeks of daily streptomycin plus isoniazid plus rifampicin. This was followed either by twice-weekly isoniazid 15 mg/kg plus rifampicin 900 mg
Inhaled corticosteroids compared with oral prednisone in patients starting long-term corticosteroid therapy for asthma. A controlled trial by the British Thoracic and Tuberculosis Association. Inhaled beclomethasone dipropionate and inhaled betamethasone valerate have been compared with oral prednisone in the treatment of 75 patients with asthma who were starting long-term corticosteroids for the first time. Both of the inhaled corticosteroids controlled asthma as well as did oral prednisone